ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Educational Symposium

Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors, CVD, and Hyporesponsiveness to Erythropoiesis-Stimulating Agents in ESKD

November 06, 2025 | 12:45 PM - 01:45 PM

Location: Room TBD2, Hilton Americas-Houston

Session Description

Anemia is a common condition in patients with CKD that reduces quality of life and increases morbidity and mortality risk. Intravenous iron and erythropoiesis-stimulating agents (ESAs) have been the treatment mainstays for CKD-associated anemia. Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are a new class of oral medications to treat anemia in patients with ESKD.

CVD is a major component of anemia-related morbidity in ESKD, and through a diverse set of mechanisms, HIF-PHIs may have positive cardiac effects. In patients who become hyporesponsive to ESAs, HIF-PHIs provide an alternative means of treating anemia. This symposium discusses potential cardiovascular effects of HIF-PHIs and summarizes cardiovascular outcomes from clinical trials. Mechanisms of hyporesponsiveness to ESAs are also explored.

Support is provided by an educational grant from Akebia Therapeutics, Inc.

Learning Objective(s)

  • Outline the mechanisms by which HIF-PHIs treat anemia in patients with kidney diseases
  • Describe the cardiovascular effects of HIF-PHIs
  • Explain the mechanisms underlying a poor response to ESAs

Learning Pathway(s)

  • Dialysis
  • Pharmacology

Moderator

Presentations